Cargando…
Diclofenac reduces the risk of Alzheimer’s disease: a pilot analysis of NSAIDs in two US veteran populations
BACKGROUND: Our aim was to determine whether specific nonsteroidal anti-inflammatory (NSAID) agents are associated with a decreased frequency of Alzheimer’s disease (AD). MATERIALS AND METHODS: Days of drug exposure were determined for diclofenac, etodolac, and naproxen using US Department of Vetera...
Autores principales: | Stuve, Olaf, Weideman, Rick A., McMahan, Danni M., Jacob, David A., Little, Bertis B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325551/ https://www.ncbi.nlm.nih.gov/pubmed/32647537 http://dx.doi.org/10.1177/1756286420935676 |
Ejemplares similares
-
Microglia as a cellular target of diclofenac therapy in Alzheimer’s disease
por: Stopschinski, Barbara E., et al.
Publicado: (2023) -
Advances in NSAID Development: Evolution of Diclofenac Products Using Pharmaceutical Technology
por: Altman, Roy, et al.
Publicado: (2015) -
NSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with Farnesoid X Receptor
por: Schmidt, Jurema, et al.
Publicado: (2015) -
Crystal structure of a new hydrate form of the NSAID sodium diclofenac
por: Angel Nieto, Ismael, et al.
Publicado: (2020) -
Utilization of a neurology specialty service by primary care providers for headache management at a tertiary care hospital
por: Vazirian, Samra, et al.
Publicado: (2022)